Olaplex (NASDAQ:OLPX) versus Dermata Therapeutics (NASDAQ:DRMAW) Head to Head Survey

Dermata Therapeutics (NASDAQ:DRMAW) and Olaplex (NASDAQ:OLPX) are both consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for Dermata Therapeutics and Olaplex, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	0	0	0	0	0.00
Olaplex	1	5	1	0	2.00

Olaplex has a consensus target price of $1.92, suggesting a potential downside of 7.11%. Given Olaplex’s stronger consensus rating and higher probable upside, analysts clearly believe Olaplex is more favorable than Dermata Therapeutics.

Profitability

This table compares Dermata Therapeutics and Olaplex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	N/A	N/A
Olaplex	-3.53%	2.23%	1.31%

Earnings and Valuation

This table compares Dermata Therapeutics and Olaplex”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
Olaplex	$425.35 million	3.27	-$9.25 million	($0.02)	-103.50

Dermata Therapeutics has higher earnings, but lower revenue than Olaplex.

Institutional and Insider Ownership

87.4% of Olaplex shares are owned by institutional investors. 4.8% of Olaplex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Olaplex beats Dermata Therapeutics on 8 of the 9 factors compared between the two stocks.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

About Olaplex

Olaplex Holdings, Inc. develops, manufactures, and sells hair care products in the United States and internationally. The company offers hair care shampoos and conditioners for use in treatment, maintenance, and protection of hair, as well as oil, moisture mask, and nourishing hair serum. It provides hair care products to professional hair salons, retailers, and everyday consumers. The company distributes its products through professional distributors in salons, directly to retailers for sale in their physical stores, e-commerce sites, and its website, Olaplex.com, as well as third party e-commerce platforms. The company was founded in 2014 and is based in Santa Barbara, California.